Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

NCT07243171 is registered in ClinicalTrials.gov with Hangzhou Sciwind Biosciences Co., Ltd. as lead sponsor.

NCT NCT07243171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07243171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 18, 2025
Completion date
April 28, 2027
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and/or obesity, weight management